Let’s set the table for Sunday’s presentation of the lung cancer immunotherapy trial known as HARMONi-2.
Last June, Summit Therapeutics created a lot of buzz — and sent its stock surging — when it announced top-line results stating its experimental drug called ivonescimab delayed tumor progression significantly more than Merck’s Keytruda in a head-to-head Phase 3 study of patients with PD-L1 positive, advanced non-small cell lung cancer.
No drug had ever beaten Keytruda directly in a lung cancer Phase 3 study prior to Summit’s surprise disclosure, but without details, questions lingered. Sunday’s HARMONi-2 presentation at the World Conference on Lung Cancer should provide the answers.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
